AC Immune SA Statistics
Share Statistics
AC Immune SA has 99.68M shares outstanding. The number of shares has increased by 0.49% in one year.
| Shares Outstanding | 99.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 61.91M |
| Failed to Deliver (FTD) Shares | 2.81K |
| FTD / Avg. Volume | 2.31% |
Short Selling Information
The latest short interest is 986.13K, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 986.13K |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 6.65 |
Valuation Ratios
The PE ratio is -6.56 and the forward PE ratio is -12.24.
| PE Ratio | -6.56 |
| Forward PE | -12.24 |
| PS Ratio | 24.06 |
| Forward PS | 5.3 |
| PB Ratio | 2.22 |
| P/FCF Ratio | -5.82 |
| PEG Ratio | n/a |
Enterprise Valuation
AC Immune SA has an Enterprise Value (EV) of 281.04M.
| EV / Earnings | -5.18 |
| EV / Sales | 18.99 |
| EV / EBITDA | -5.42 |
| EV / EBIT | -5.24 |
| EV / FCF | -4.59 |
Financial Position
The company has a current ratio of 9.22, with a Debt / Equity ratio of 0.
| Current Ratio | 9.22 |
| Quick Ratio | 9.22 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -304.68 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -32.68%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -32.68% |
| Revenue Per Employee | 111.29K |
| Profits Per Employee | -407.77K |
| Employee Count | 133 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 10.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -30.37% in the last 52 weeks. The beta is 1.28, so AC Immune SA's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -30.37% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 3.29 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 121.72K |
Income Statement
In the last 12 months, AC Immune SA had revenue of 14.80M and earned -54.23M in profits. Earnings per share was -0.64.
| Revenue | 14.80M |
| Gross Profit | -39.80M |
| Operating Income | -53.62M |
| Net Income | -54.23M |
| EBITDA | -51.83M |
| EBIT | -53.62M |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 78.49M in cash and 3.50M in debt, giving a net cash position of 75.00M.
| Cash & Cash Equivalents | 78.49M |
| Total Debt | 3.50M |
| Net Cash | 75.00M |
| Retained Earnings | -316.20M |
| Total Assets | 244.25M |
| Working Capital | 86.60M |
Cash Flow
In the last 12 months, operating cash flow was -60.41M and capital expenditures -801.00K, giving a free cash flow of -61.21M.
| Operating Cash Flow | -60.41M |
| Capital Expenditures | -801.00K |
| Free Cash Flow | -61.21M |
| FCF Per Share | -0.72 |
Margins
Gross margin is -26.89K%, with operating and profit margins of -36.23K% and -36.64K%.
| Gross Margin | -26.89K% |
| Operating Margin | -36.23K% |
| Pretax Margin | -36.63K% |
| Profit Margin | -36.64K% |
| EBITDA Margin | -350.19% |
| EBIT Margin | -362.3% |
| FCF Margin | -413.55% |
Dividends & Yields
ACIU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -21.48% |
| FCF Yield | -20.57% |
Analyst Forecast
The average price target for ACIU is $12, which is 302.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 302.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -0.56 |
| Piotroski F-Score | 4 |